Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9963862 | 0.84 | SMN1; SMN2 (0.38) | EPHX1NAAACYP19A1HTTCYP2C19 | |
| SCHEMBL24023300 | 0.81 | EPHX1 (0.40) | EPHX1NAAACYP19A1HTTCYP2C19 | |
| SCHEMBL9966158 | 0.78 | EPHX1 (0.45) | EPHX1NAAACYP19A1HTTCYP2C19 | |
| SCHEMBL5542628 | 0.77 | CYP19A1 (0.42) | EPHX1NAAACYP19A1HTTCYP2C19 | |
| SCHEMBL13130088 | 0.76 | EPHX1 (0.41) | EPHX1NAAACYP19A1HTTCYP2C19 | |
| SCHEMBL28499766 | 0.75 | NAAA (0.42) | EPHX1NAAACYP19A1HTTCYP2C19 | |
| SCHEMBL20207259 | 0.75 | NAAA (0.49) | EPHX1NAAACYP19A1HTTCYP2C19 | |
| SCHEMBL5512762 | 0.75 | CYP19A1 (0.40) | EPHX1NAAACYP19A1HTTCYP2C19 | |
| SCHEMBL24023313 | 0.75 | EPHX1 (0.41) | EPHX1NAAACYP19A1HTTCYP2C19 | |
| SCHEMBL18895904 | 0.75 | EPHX1 (0.41) | EPHX1NAAACYP19A1HTTCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-03-18 | — | — | US | disclosed |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-02-22 | — | — | US | disclosed |
| US-9828367-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-9724359-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-08-08 | — | — | US | disclosed |
| US-20170020904-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020904-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | EPHX1 607/4885NAAA 256/4885CYP19A1 2679/4885 |
| US-20210079017-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | EPHX1 641/4885NAAA 227/4885CYP19A1 2857/4885 |
| US-20180051023-A1 | NEPRILYSIN INHIBITORS | MME, REN, EDNRB | EPHX1 974/4885NAAA 142/4885CYP19A1 2592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.